Acquisition of Ohr Pharmaceutical, Inc. - Additional Information (Details) |
Jul. 12, 2019
USD ($)
|
|---|---|
| Acquisition of Ohr Pharmaceutical, Inc. | |
| Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 6 months |
| Business Combination, Consideration Transferred | $ 12,661,908 |
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill | $ 250,000 |
| Private NeuBase Ownership percentage of Ohr | 85.00% |
| X | ||||||||||
- Definition The value represents private Neubase ownership percentage of ohr. No definition available.
|
| X | ||||||||||
- Definition Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of intangible assets, excluding goodwill, acquired at the acquisition date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|